2026 Recipients


Tyler Novak


Photo of Tyler Novak.

Tyler Novak | Biomedical Engineering

Director of Drug Delivery Strategy and Innovation, Gilead Sciences

Tyler Novak, PhD, has spent his career advancing technologies that change how medicines and biomedical products reach patients. At Gilead Sciences, where he is Director of Drug Delivery Strategy and Innovation, Dr. Novak leads strategy and technology development for next-generation drug delivery, including long-acting therapies, advanced formulations and combination products. His work has supported Gilead’s long-acting HIV portfolio, including programs involving lenacapavir, while helping establish a longer-term technology strategy for drug delivery across the company.

Dr. Novak’s impact extends across pharmaceuticals, medical devices and regenerative medicine. At Intersect ENT, he directed key technical programs during the company’s $1.1 billion acquisition by Medtronic. Earlier, at Cook Biotech, he led the development of technologies for peripheral nerve repair and directed a regenerative tricuspid heart valve program from concept into clinical investigation. His career has consistently centered on moving ambitious biomedical ideas from scientific possibility toward practical solutions for patients.

Dr. Novak is an inventor and published researcher whose work spans drug delivery, biomaterials, tissue engineering and regenerative medicine. He serves on the governing board of the Subcutaneous Drug Development and Delivery Consortium and has returned to Purdue as Adjunct Faculty in Biomedical Engineering, where he helps prepare the next generation of engineers to translate unmet patient needs into new healthcare products. Novak earned both his BS and PhD in Biomedical Engineering from Purdue.